Company Description
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States.
The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors.
The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets.
Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
| Country | United States |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 62 |
| CEO | Eric Poma |
Contact Details
Address: 9301 Amberglen Boulevard, Suite 100 Austin, Texas 78729 United States | |
| Phone | 512 869 1555 |
| Website | mtem.com |
Stock Details
| Ticker Symbol | MTEM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001183765 |
| CUSIP Number | 608550109 |
| ISIN Number | US6085502085 |
| Employer ID | 94-3409596 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Eric E. Poma Ph.D. | Chief Executive Officer, Chief Scientific Officer and Director |
| Jason S Kim | President, Chief Financial Officer, Treasurer and Principal Accounting Officer |
| Kristen Quigley B.A. | Chief Operating Officer |
| Dr. Grace Kim | Chief Strategy Officer and Head of IR |
| Dr. Michelle Iwamoto-Fan J.D., Ph.D. | Senior Vice President and General Counsel |
| Dr. Joseph Phillips Ph.D. | Senior Vice President and Head of CMC Development |
| Dr. Chris Moore Ph.D. | Senior Vice President and Head of Preclinical Development and Translational Medicine |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 28, 2024 | DEF 14A | Other definitive proxy statements |
| Oct 17, 2024 | PRE 14A | Other preliminary proxy statements |
| Oct 11, 2024 | 8-K | Current Report |
| Oct 4, 2024 | 8-K | Current Report |
| Sep 27, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 10-Q | Quarterly Report |